Stock AnalizDenali Therapeutics Inc. DNLI
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2017 · data as of November 13, 2026
Denali Therapeutics Inc. (DNLI) is a healthcare company listed in the US with a market value of about $3.0B. In the twelve months to September 30, 2026 it had revenue of $21M and net income of -$314M, a net margin of -1470.5%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -27%.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21M | $0 | $0 | $331M | $108M | $49M | $336M | $27M | $129M | $0 | $0 |
| Net income | -$314M | -$513M | -$423M | -$145M | -$326M | -$291M | $71M | -$198M | -$36M | -$88M | -$87M |
| Free cash flow | -$450M | -$422M | -$364M | -$371M | -$263M | -$220M | $413M | -$169M | $47M | -$80M | -$78M |
| EPS (diluted) | $-1.73 | $-2.97 | $-2.57 | $-1.06 | $-2.60 | $-2.39 | $0.63 | $-2.07 | $-0.39 | $-5.89 | $-13.49 |
| Net margin | -1470.5% | — | — | -43.9% | -300.6% | -597.1% | 21.2% | -740.7% | -28.1% | — | — |
| ROIC | — | -41.8% | -30.2% | -14.3% | -24.4% | -22.8% | 4.1% | -36.0% | -6.7% | -15.3% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 16 analysts is $36.19, 93% above the current price; targets range from $24.00 to $46.00; the consensus rating is “Strong buy”; expected EPS is $-2.05 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Denali Therapeutics pay a dividend?
Not currently.
Is Denali Therapeutics a good stock to buy?
We do not give buy or sell advice. Denali Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.